I am a Hematology/Oncology Fellow & Physician-Scientist at Stanford in the Translational Investigator Pathway.
My research is at the intersection of hematology/oncology and computational ‘omics. I am interested in plasma cell dyscrasias, amyloidosis, precision oncology, and how large datasets can be used for risk stratification, treatment decisions, and drug discovery to improve patient outcomes.
Before medical school, I spent five years as a computational biologist at the Broad Institute of MIT & Harvard, working with Dr. Gad Getz’s lab and the GTEx Consortium. Select projects include co-leading a pan-cancer proteogenomics flagship study with the CPTAC Consortium, a single-nucleus, cross-tissue transcriptomic atlas of the human body with the GTEx Consortium, and genomic risk stratification of smoldering multiple myeloma.
Methodologically, my work spans single-cell genomics, multi-omics integration, structural proteomics, and algorithm development. My tools / repositories are available here, my publications are available here, and my training is further detailed here.
news
| Jul 01, 2026 | Started Hematology/Oncology Fellowship at Stanford. |
|---|---|
| Jun 01, 2025 | New paper in Nature Genetics on tamoxifen-induced PI3K activation in early-stage uterine cancer (Kübler et al., 2025). |
| Feb 01, 2025 | Published a contemporary treatment review on AL amyloidosis for nephrologists in Nephrology Dialysis Transplantation (Anand et al., 2025). |
| Aug 01, 2024 | New paper in the American Journal of Hematology: machine-learning based subgroups of systemic AL amyloidosis and their association with mortality and end-stage kidney disease (Anand et al., 2024). |
| Jun 17, 2024 | Started Internal Medicine residency at Stanford, in the Translational Investigator Pathway. |